Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RTU 1096

Drug Profile

RTU 1096

Alternative Names: RTU-1096; VAP-1 inhibitors - Mallinckrodt

Latest Information Update: 21 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator R-Tech Ueno
  • Developer Hokkaido University; Kyushu University; Sucampo Pharmaceuticals
  • Class Anti-inflammatories; Antipsoriatics; Skin disorder therapies
  • Mechanism of Action AOC3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Atopic dermatitis; Cataracts; Contact dermatitis; Diabetic macular oedema; Diabetic neuropathies; Diabetic retinopathy; Psoriasis

Most Recent Events

  • 13 Feb 2018 Sucampo Pharmaceuticals has been acquired by Mallinckrodt
  • 09 Nov 2016 Discontinued - Phase-I for Atopic dermatitis (In volunteers) in Japan (PO) before November 2016
  • 09 Nov 2016 Discontinued - Phase-I for Diabetic macular oedema in Japan (PO) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top